A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
暂无分享,去创建一个
Robert Brown | J. Plumb | T. Evans | J. Tjørnelund | L. Vidal | N. Steele | P. Knoblauch | P. Buhl-Jensen | C. E. Ooi | J. Debono | A. Rasmussen
[1] J. Grem,et al. A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors , 2007 .
[2] P. B. Jensen,et al. A phase I/II study of the safety and anti-cancer activity of IV-administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors , 2007 .
[3] Minoru Yoshida,et al. [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[4] E. Sausville,et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] N. Funata,et al. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. , 2004, International journal of oncology.
[6] Marie Joseph,et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] L. Schwartz,et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] P. Finn,et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.
[9] P. Therasse,et al. Evaluation of response: new and standard criteria. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] L. Grochow,et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] M. Krstic-Demonacos,et al. Acetylation control of the retinoblastoma tumour-suppressor protein , 2001, Nature Cell Biology.
[12] P. Marks,et al. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.
[13] Wei Gu,et al. Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.
[14] R. Fisher,et al. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] C. Van Lint,et al. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.